Metformin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='97/975914/Cv/2'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='97/975914/Cv/2'> | ||
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. See also [https://en.wikipedia.org/wiki/Metformin]. | Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. See also [https://en.wikipedia.org/wiki/Metformin Metformin]. | ||
The molecular mechanism of metformin is not completely understood. Multiple potential mechanisms of action have been proposed: inhibition of the mitochondrial respiratory chain ([[complex I]]), activation of [[AMP-activated protein kinase]] (AMPK), inhibition of glucagon-induced elevation of cyclic adenosine monophosphate (cAMP) with reduced activation of [[protein kinase A]] (PKA), [[complex IV]]–mediated inhibition of the GPD2 variant of mitochondrial [[glycerol-3-phosphate dehydrogenase]] (thereby reducing glycerol-derived hepatic [[gluconeogenesis]]), and an effect on gut microbiota.<ref name="a23">PMID:35238637</ref><ref name="a99">PMID:23835523</ref><ref name="a100">PMID:23840042</ref><ref name="a101">PMID:24847880</ref> | The molecular mechanism of metformin is not completely understood. Multiple potential mechanisms of action have been proposed: inhibition of the mitochondrial respiratory chain ([[complex I]]), activation of [[AMP-activated protein kinase]] (AMPK), inhibition of glucagon-induced elevation of cyclic adenosine monophosphate (cAMP) with reduced activation of [[protein kinase A]] (PKA), [[complex IV]]–mediated inhibition of the GPD2 variant of mitochondrial [[glycerol-3-phosphate dehydrogenase]] (thereby reducing glycerol-derived hepatic [[gluconeogenesis]]), and an effect on gut microbiota.<ref name="a23">PMID:35238637</ref><ref name="a99">PMID:23835523</ref><ref name="a100">PMID:23840042</ref><ref name="a101">PMID:24847880</ref> | ||